Convatec announced that it has secured two new group purchasing agreements in the Enterostomal Therapy Products category with Premier, Inc., a technology‑driven healthcare improvement company that was acquired by Patient Square Capital on November 25 2025 for $28.25 per share. The contracts, which will become effective on April 1 2026, give Premier access to Convatec’s full ostomy product line, including the me+ support program, and provide Premier’s members with enhanced value and savings.
The agreements are expected to generate additional fee‑share revenue for Premier’s Supply Chain Services segment, which had seen a 7% decline in net revenue in Q1 FY2025. While Convatec has not disclosed specific revenue figures, the contracts are projected to add a significant recurring stream in a high‑margin category, reinforcing Convatec’s position in the specialty‑product market and supporting its growth trajectory.
Premier’s transition to a private company does not alter the contractual relationship; the agreements remain a strategic win for Convatec and a means for Premier to expand its portfolio and offset prior revenue declines. The deal underscores continued demand for specialty products within Premier’s member network and highlights the value of Convatec’s ostomy solutions in a market that prioritizes patient support and cost efficiency.
From Convatec’s perspective, the contracts deepen its presence in the United States, where the ostomy market is highly fragmented and price sensitive. By partnering with a large GPO, Convatec gains access to a broad base of hospitals and health systems, potentially driving incremental sales and market share in a category that has historically delivered strong margins.
For Premier, the agreements add a new source of fee‑share revenue and broaden its product offering in a high‑margin therapeutic area. The partnership aligns with Premier’s strategy to strengthen its supply‑chain platform and deliver actionable intelligence to members, even as the company navigates the transition to private ownership.
Overall, the agreements represent a strategic milestone for Convatec and illustrate the continued relevance of GPO partnerships in expanding specialty‑product reach and generating recurring revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.